Tyrosine kinase inhibitors (TKIs) are recommended treatment options for patients with CML,3, 4, 5, 6 with all currently approved TKIs targeting the adenosine triphosphate (ATP) binding site of ABL1.3, 4, 5, 6. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.